|
Biomx Inc
PHGEU's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Biomx Inc 's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.04 %
Biomx Inc faced net loss in contrast to the net income a year ago in II. Quarter 2024
• More on PHGEU's Growth
|
|
Biomx Inc current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Biomx Inc realized cash reduction of $ 0.09 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 7.08.
• More on PHGEU's Valuation
|
|
|
|
|
Biomx Inc current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.
Biomx Inc realized cash outflow of $ 0.09per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 7.08.
• More on PHGEU's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com